These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17693134)

  • 1. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
    Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
    Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
    J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
    Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
    J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of
    van Rossum PSN; Fried DV; Zhang L; Hofstetter WL; Ho L; Meijer GJ; Carter BW; Court LE; Lin SH
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):71-80. PubMed ID: 27511188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
    Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
    Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET/CT based response-adapted treatment.
    de Geus-Oei LF; Vriens D; Arens AI; Hutchings M; Oyen WJ
    Cancer Imaging; 2012 Sep; 12(2):324-35. PubMed ID: 23023063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study.
    Obermannova R; Selingerova I; Rehak Z; Jedlicka V; Slavik M; Fabian P; Novotny I; Zemanova M; Studentova H; Grell P; Zdrazilova Dubska L; Demlova R; Harustiak T; Hejnova R; Kiss I; Vyzula R
    Ther Adv Med Oncol; 2021; 13():17588359211065153. PubMed ID: 35035533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
    Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
    Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Fluorouracil-Based Chemotherapy and PET-Adapted Consolidation Chemoradiation with Esophagectomy for High-Risk Gastroesophageal Adenocarcinoma.
    Sinnamon AJ; Mehta R; Saeed S; Lauwers GY; Palm RF; Frakes JM; Hoffe SE; Baldonado JJ; Fontaine JP; Pimiento JM
    Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686650
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma.
    Sinclair R; Navidi M; Griffin SM; Sumpter K
    Ann R Coll Surg Engl; 2016 Jul; 98(6):396-400. PubMed ID: 27138851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.
    Harada K; Wang X; Shimodaira Y; Sagebiel T; Bhutani MS; Lee JH; Weston B; Elimova E; Lin Q; Amlashi FG; Mizrak Kaya D; Lopez A; Blum Murphy MA; Roth JA; Swisher SG; Skinner HD; Hofstetter WL; Rogers JE; Thomas I; Maru DM; Komaki R; Walsh G; Ajani JA
    Target Oncol; 2018 Feb; 13(1):99-106. PubMed ID: 29218623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG).
    Kita R; Yanagimoto Y; Imazeki H; Booka E; Tsushima T; Mizusawa J; Sasaki K; Fukuda H; Kurokawa Y; Takeuchi H; Kato K; Kitagawa Y; Boku N; Yoshikawa T; Terashima M;
    Jpn J Clin Oncol; 2024 Feb; 54(2):206-211. PubMed ID: 37952093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy followed by response evaluation and esophagectomy for advanced esophageal cancer.
    van der Zijden CJ; van der Sluis PC; Mostert B; Nuyttens JJME; Spaander MCW; Toxopeus ELA; Valkema R; Beerepoot LV; van Halteren HK; Lagarde SM; Wijnhoven BPL
    Eur J Surg Oncol; 2024 Mar; 50(3):107968. PubMed ID: 38241878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.
    Harada K; Mizrak Kaya D; Lopez A; Baba H; Ajani JA
    Ann Transl Med; 2018 Feb; 6(4):80. PubMed ID: 29666803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab.
    Gil-Delgado MA; Lucidarme O; Bachet JB; Mahi N; Khayat D
    Case Rep Gastroenterol; 2018; 12(2):532-539. PubMed ID: 30283289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy.
    Brosda S; Aoude LG; Bonazzi VF; Patel K; Lonie JM; Belle CJ; Newell F; Koufariotis LT; Addala V; Naeini MM; ; Pearson JV; Krause L; Waddell N; Barbour AP
    Genome Med; 2024 Jul; 16(1):90. PubMed ID: 39020404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: The molecular fingerprint and the clinical implication of an exceptional response to neoadjuvant therapy in a metastatic cardia adenocarcinoma.
    Lorenzon L; Campisi A; Di Paolo A; Giuliante F; Buttitta F; D'Ugo D
    Front Surg; 2024; 11():1297083. PubMed ID: 38689602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias.
    Simon R; Makuch RW
    Stat Med; 1984; 3(1):35-44. PubMed ID: 6729287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Super-responders to bidirectional neoadjuvant chemotherapy showed prolonged survival.
    Sugarbaker PH; Van der Speeten K
    J Gastrointest Oncol; 2021 Apr; 12(Suppl 1):S57-S58. PubMed ID: 33970162
    [No Abstract]   [Full Text] [Related]  

  • 20. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.